Hyalgan (Sodium Hyaluronate)

Hyalgan is indicated for the symptomatic treatment of osteoarthritis in several joints, where it is administered directly into the affected joint space.

• Knee osteoarthritis, providing intra‑articular supplementation of hyaluronic acid.
• Hip osteoarthritis, used to improve joint mechanics and reduce pain.
• Temporomandibular joint osteoarthritis, administered to enhance joint function.
• As an adjunct to physical therapy or rehabilitation programs to support functional recovery.
• In patients who have an inadequate response or contraindication to oral NSAIDs.

• Hyalgan delivers sodium hyaluronate directly into the joint cavity, where it integrates with the existing synovial fluid. The polymer restores the normal concentration and molecular weight of hyaluronic acid, enhancing the viscoelasticity of the fluid. This improved viscoelasticity increases lubrication, reduces friction, and augments shock‑absorption capacity of the joint, thereby helping to protect cartilage and improve joint mobility and overall joint health.

Adverse reactions to intra‑articular Hyalgan are generally related to the injection procedure and the product composition.

Common

• Transient pain or swelling at the injection site.
• Mild warmth or flushing in the treated joint.
• Temporary stiffness or reduced range of motion lasting a few days.
• Low‑grade headache or fatigue.

Serious

• Acute joint infection (septic arthritis).
• Allergic reaction presenting as rash, urticaria, or angioedema.
• Persistent severe joint pain or effusion requiring medical evaluation.
• Rare cases of tendon or ligament injury at the injection site.

Before using Hyalgan, clinicians should assess patient history and joint condition to minimize risks.

• Confirm diagnosis of osteoarthritis and rule out active joint infection.
• Evaluate for hypersensitivity to hyaluronic acid or any component of the formulation.
• Use caution in patients with bleeding disorders or those receiving anticoagulant therapy.
• Consider alternative therapy for pregnant or nursing women, as safety data are limited.
• Monitor for signs of infection or severe inflammation after each injection.
• Avoid repeated injections in the same joint within a short interval without medical justification.

Hyalgan may interact with other agents that affect joint health or bleeding risk.

Avoid

• Concurrent intra‑articular corticosteroid injections in the same joint within a short period.
• Use with intra‑articular antibiotics or other viscosupplements without physician guidance.

Use with caution

• Systemic anticoagulants (e.g., warfarin, direct oral anticoagulants) due to potential bleeding at the injection site.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase local irritation.
• Disease‑modifying osteoarthritis drugs (DMOADs) where combined effects are not well studied.
• High‑dose vitamin C or supplements that could affect cartilage metabolism.